[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Southern College of Optometry\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":178},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,68,95,117,135,154],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100640260","clinical-performance-of-verofilcon-a-toric-contact-lenses-100640260",false,"NCT07586982","Clinical Performance of Verofilcon A Toric Contact Lenses","Clinical Performance of Verofilcon A Toric Contact Lenses in Satisfied Wearers of Senofilcon A Toric Contact Lenses With Blue Light Filtration","Inclusion Criteria:\n\n* Adults, ≥40-year-old, CL wearers with best-corrected 20\u002F20 distance visual acuity or better.\n* Requiring +0.75 ADD or more at standard near distance of 40 cm.\n* Participants will be required to have worn reusable silicone hydrogel toric CLs in the past year and still at a minimum wearing the CLs occasionally without having significant discomfort or dryness.\n* All participants will be required to have a CLDEQ-8 score \\\u003C12.\n* Participants will be required to be able to wear Total 30MFT CLs (presbyopic plus astigmatism both ≥0.75D OD and OS).\n* Astigmatism ranging from 0.75 D to 2.50 D in each eye.\n* Participants will be required to wear the study CLs for ≥13 hours each day with no overnight wear.\n* Willing to wear study CLs for ≥16 hours on the Day 1 (1st full day), Day 14, and Day 29 when responses will be collected via text message.\n* Participants will be willing to wear the CL every day of the week.\n* Participants will be required to provide a glasses prescription that is less than 3 years old.\n* Visual acuity with habitual reusable silicone hydrogel toric CLs is 20\u002F25 or better in each eye.\n\nExclusion Criteria:\n\n* Have worn Total30 MFT in the past\n* Are past rigid CL wearers\n* Are currently wearing monovision CLs\n* Have a history of being diagnosed with dry eye or ocular allergies\n* Have known systemic health conditions that are thought to alter tear film physiology\n* Have a history of viral eye disease\n* Have a history of ocular surgery\n* Have a history of severe ocular trauma\n* Have a history of corneal dystrophies or degenerations\n* Have active ocular infection or inflammation\n* Are currently using isotretinoin-derivatives or ocular medications\n* Are pregnant or breast feeding",true,"ALL","18 Years","40 Years",{"count":21,"type":22},32,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to \\[primary purpose: is to determine if Total30 Multi focal toric conntact lensesare comfortable and the willigness for those who have previously worn reusable toric contact lenses are willing to stay in Total30 MFT after 1 month of wear during the duration of the study. Healthy previous reusable toric contact lens weareres will be refit into total30 MFT contact lenses and will be asked to gauge their comfort while wearing the lenses. Healthy adult participants who are presybyopic between the ages of 18-40 can participant, sex and gender are not disqualifiers unless the participant is pregnant or breast feeding. The main question\\[s\\] it aims to answer \\[is\u002Fare\\]\n\n\\[primary hypothesis or outcome measure 1Proportions of toric CL wearers who have positive visual acuity scores in comfort and vision after one month of wear.\n\n\\[primary hypothesis or outcome measure 2\\]? Contact lens dry eye-8 scores will be less than 12 indicating high levels of comfort after one month of wear.",[28,29],"Contact Lenses","Presbyopia",[31,32],"Optometry","Contact lens comfort","RECRUITING","2026-05-07",{"date":36,"type":37},"2026-05-14","ACTUAL",{"date":39,"type":22},"2026-04",{"date":41,"type":22},"2026-09",{"name":43,"class":44},"Southern College of Optometry","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":16,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":45},"100621852","effects-of-acute-sugar-intake-on-choroidal-thickness-100621852","NCT07376005","Effects of Acute Sugar Intake on Choroidal Thickness","Inclusion Criteria:\n\n* In order to be eligible for enrolment, each subject must have less than 6 diopters of spherical equivalent refractive error, and have no existing diagnosis of diabetes or pre-diabetes.\n\nExclusion Criteria:\n\n* Any potential subject with known retinal pathology will be excluded. Any potential subject with any other known systemic or ocular conditions that may impact their ability to participate in the study or provide generalizable data will also be excluded.","21 Years","35 Years",{"count":55,"type":22},47,[25],"This study aims to bridge that gap by investigating how acute sugar intake influences choroidal thickness.",[59],"Choroid","2026-01-21",{"date":62,"type":37},"2026-01-29",{"date":64,"type":22},"2026-01",{"date":66,"type":22},"2026-05",{"name":43,"class":44},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":78,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":4},"100613506","phase-4-switching-from-xiidra-to-tryptyr-100613506","NCT07267481","Switching From Xiidra to TRYPTYR","Efficacy of Switching Participants Treated With Xiidra to TRYPTYR","Inclusion Criteria:\n\n* Adults ≥18 years of age.\n* Have a history of DED for at least the past 6 months.\n* Are currently using Xiidra as directed by their eye care provider for ≥1 month.\n* Are symptomatic as determined with SPEED (≥7) and have an abnormal Schirmer test score \\[≥2 to \\\u003C10 mm\u002F5 min\\]) at Screening\u002FBaseline. If Shirmer only qualifies for one eye, that will be the study eye. If Shirmer qualifies for both eyes, the right eye will be the study eye.\n* Have corrected distance visual acuity of 20\u002F40 or better.\n* Willing to discontinue contact lens wear 24 hours prior to screening visit and throughout the study.\n\nExclusion Criteria:\n\n* Have a systemic health condition that is known to alter tear film physiology (e.g., primary and secondary Sjögren's syndrome).\n* Have a history of ocular surgery within the past 12 months.\n* Have a history of severe ocular trauma, active ocular infection or inflammation that is not dry eye related.\n* Punctal plugs in place for \\\u003C 3 months and\u002For Lacrifill in place for \\> 5 months.\n* Have ever used Accutane\n* Currently using ocular medications, including topical anti-inflammatory drops, (other than Xiidra) 1 month prior to enrollment\n* Any artificial tear use at enrollment must remain consistent throughout the study.\n* Are pregnant or breast feeding.\n* Have had a physical meibomian gland treatment withing 1 month of enrollment.\n* Initiated, discontinued or changed dose of a systemic medication known to cause ocular drying (e.g., antihistamines or tricyclic antidepressants) within 14 days of the screening visit.\n* Have a condition or be in a situation, which in the investigator's opinion, may put the participant at significant risk, may confound the results, or may significantly interfere with their study participation.","99 Years",{"count":77,"type":22},100,[79],"PHASE4","To determine the efficacy of switching participants who are being treated with Xiidra to acoltremon 0.003%.\n\nHypothesis: Switching to acoltremon 0.003% will greatly improve the signs and symptoms of participants who were being treated with Xiidra at 28 days post-treatment compared to baseline.",[82,83,84,85],"Dry Eye","Dry Eyes Chronic","Dry Eye Syndromes","Eye Diseases","NOT_YET_RECRUITING","2025-11-25",{"date":89,"type":37},"2025-12-05",{"date":91,"type":22},"2025-12-15",{"date":93,"type":22},"2026-05-01",{"name":43,"class":44},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":110,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},"100613465","phase-4-impact-of-tryptyr-on-a-patients-quality-of-life-and-ability-to-perform-work-100613465","NCT07266948","Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work","Evaluating the Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work","TRYPTYR ADL","Inclusion Criteria:\n\n* Adults ≥18 years of age.\n* Have a history of DED for at least the past 6 months.\n* Are currently using Restasis as directed by their eye care provider for ≥1 month.\n* Participant intends to stop Restasis in the near future because and expressed dissatisfaction with effectiveness of Restasis in reducing dry eye symptoms..\n* Are symptomatic as determined with the Eye Dryness visual analog scale (VAS) (Score ≥50), SPEED (≥7), and have an abnormal Schirmer test score \\[≥2 to \\\u003C10 mm\u002F5 min\\]) at Screening\u002FBaseline.\n* Have corrected distance visual acuity of 20\u002F100 or better.\n* Willing to discontinue contact lens wear throughout the study.\n\nExclusion Criteria:\n\n* Have a systemic health condition that is known to alter tear film physiology (e.g., primary and secondary Sjögren's syndrome).\n* Have a history of ocular surgery within the past 12 months.\n* Have a history of severe ocular trauma, active ocular infection or inflammation that is not dry eye related.\n* Punctal plugs in place for \\\u003C 3 months and\u002For Lacrifill in place for \\> 5 months.\n* Have ever used Accutane or are currently using ocular medications (must washout from all dry eye medications\u002Ftreatments at least 1 week before entry, except for Restasis).\n* Use of artificial tears within 2 hours prior to the baseline visit or during the study.\n* Are pregnant or breast feeding.\n* Have had a physical meibomian gland treatment withing 1 month of enrollment.\n* Have a condition or be in a situation, which in the investigator's opinion, may put the participant at significant risk, may confound the results, or may significantly interfere with their study participation.","75 Years",{"count":105,"type":22},40,[79],"This 1-month, 3-visit study will be conducted at the Southern College of Optometry (Memphis, TN), Kannarr Eye Care, LLC (Pittsburg, KS) and Complete Eye Care of Medina (Minneapolis, MN). Adults ≥18 years of age who have been diagnosed with DED for at least 6 months and who are currently symptomatic (Eye Dryness VAS Score ≥40) will be recruited. Subjects will have an abnormal Schirmer test of \\\u003C10 mm\u002F5 min. Subjects will also be required to score ≤70 on the IDEEL Quality of Life (QoL) Work domain to ensure that their DED symptoms are significantly impacting their ability to do work.9 Subjects will be required to have corrected distance visual acuity of 20\u002F32 (0.2 logMAR) or better.",[82,85,109],"Eyes Dry Chronic",{"date":89,"type":37},{"date":112,"type":37},"2025-11-01",{"date":114,"type":22},"2026-03-01",{"name":43,"class":44},3,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":23,"phases":125,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":129,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":4},"100613492","phase-4-switching-from-restasis-to-tryptyr-100613492","NCT07267299","Switching From Restasis to TRYPTYR","Efficacy of Switching Participants Treated With Restasis to TRYPTYR","100 Years",{"count":77,"type":22},[79],"Switching to acoltremon 0.003% will significantly improve the signs and symptoms of participants who were being treated with Restasis at 28 days post-treatment compared to baseline. Dry eye disease (DED) is a prevalent condition that commonly affects patients of working age in addition to the elderly. DED is a complex condition that results in ocular symptoms such as dryness and burning and signs such as decreased tear production (aqueous deficient DED) or increased tear evaporation (evaporative DED). Unfortunately, there is not a perfect correlation between DED signs and symptoms, which makes diagnosis and timely treatment challenging.",[82,85,128],"Chronic Dry Eye",{"date":89,"type":37},{"date":131,"type":22},"2025-12-01",{"date":133,"type":22},"2026-05-15",{"name":43,"class":44},{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":142,"targetDuration":4,"studyType":23,"phases":143,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":45},"100589514","acuvue-oaysis-contact-lens-wearers-being-refit-into-p7-contact-lenses-100589514","NCT06955403","Acuvue Oaysis Contact Lens Wearers Being Refit Into P7 Contact Lenses","How Does PRECISION7® for Astigmatism Perform in Current and Successful Acuvue® Oasys for Astigmatism Wearers?","• Inclusion Criteria: Adults, 18- to 40-year-old, AOA CL wearers with best-corrected 20\u002F20 visual acuity or better.\n\n* Participants will be required to have worn AOA CLs for at least 3 months in the past year and currently wearing these CLs.\n* All participants will be required to have a CLDEQ-8 score \\\u003C12 while wearing their habitual CLs (AOA CLs) and to indicate that they are satisfied with AOA CLs (Yes\u002FNo).\n* Participants will be required to be able to wear P7A CLs (astigmatism ≥0.75D OD\u002FOS).\n* Astigmatism ranging from 0.75 D to 2.50 D in each eye\n* Participants will be required to wear the study CLs for ≥13 hours with no overnight wear\n* Participants will be willing to wear the CL every day of the week, except during the washout period\n* Participants will be required to provide a glasses prescription that is less than 3 years old\n* \\-\n* Exclusion Criteria:\n* \\- Have presbyopia and\u002For need a reading add as determined during their initial manifest refraction\n* Have worn P7A in the past\n* Are past rigid CL wearers\n* Have a history of being diagnosed with dry eye or ocular allergies\n* Have known systemic health conditions that are thought to alter tear film physiology\n* Have a history of viral eye disease\n* Have a history of ocular surgery\n* Have a history of severe ocular trauma\n* Have a history of corneal dystrophies or degenerations\n* Have active ocular infection or inflammation\n* Are currently using isotretinoin-derivatives or ocular medications\n* Are pregnant or breast feeding",{"count":105,"type":22},[25],"Determine the likelihood of successfully refitting a satisfied AOA CL wearers into P7A CLs",[146],"Contact Lens Comfort",{"date":148,"type":37},"2025-11-26",{"date":150,"type":37},"2025-04-15",{"date":152,"type":22},"2025-11-30",{"name":43,"class":44},{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":17,"minAge":161,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":23,"phases":165,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":177},"100601647","phase-4-quality-of-life-in-presbyopic-patients-who-are-treated-with-qlosi-100601647","NCT07113210","Quality of Life in Presbyopic Patients Who Are Treated With Qlosi","Understanding Quality of Life in Presbyopic Patients Who Are Treated With Qlosi","Inclusion Criteria:\n\n* Subjects who are 45-64 years old (inclusive) at the time of screening.\n* Be able and willing to provide written informed consent and sign a Health Information Portability and Accountability Act (HIPAA) form prior to any study procedure being performed.\n* Be able and willing to follow all instructions and attend study visits.\n* Have text messaging capabilities on their phone.\n* Self-reported complaints of near vision blur when fully corrected at distance.\n* Study confirmed near add that is between +0.75 D to +2.00 D OD\u002FOS (inclusive).\n* Spherical distance prescription between +1.00 D to -4.00 D OD\u002FOS (inclusive).\n* Cylinder power less than or equal to -1.00 D OD\u002FOS.\n* Best-corrected visual acuity (BCVA) at distance of 0.00 logMAR (20\u002F20 Snellen equivalent) or better OD\u002FOS.\n\nExclusion Criteria:\n\n* Known hypersensitivity to any ingredient in the study drops.\n* Any active ocular condition that may confound study results (e.g., dry eye, allergy, conjunctivitis, ocular infection).\n* Any use of prescription eye drops 1 week before screening or during the study.\n* Any past use of the study drops.\n* Any contact lens use for the duration of the study.\n* Artificial tears or lubricant eye drops use on the day of or during any study visits.\n* Clinically significant abnormal findings (e.g., central corneal scar) on a slit lamp exam in either eye documented at screening or a known history of a clinically significant slit-lamp finding in either eye that could confound study results.\n* Have had an ocular surgical intervention within 6 months of the screening visit or planned surgical intervention during the study.\n* A female of childbearing potential who is currently pregnant, nursing, or planning a pregnancy.\n* Any visible retinal findings noted upon a dilated fundus examination known to be a risk for use of study treatment (as determined by the investigator).","45 Years","64 Years",{"count":164,"type":22},36,[79],"The goal of this clinical trial is to determine how Qlosi™ (pilocarpine HCL ophthalmic solution) 0.4%impacts the quality of life of participants with presbyopia by using a battery of validated and investigator-developed instruments\n\n* Improvement in presbyopic symptoms as measured with the Near Activity Visual Questionnaire-Presbyopia (NAVQ-P) when using Qlosi™ at week 4 compared to baseline (continuous variable).\n* Improvement in presbyopic symptoms as measured with the Visual Quality of Life with Time Survey (VisQualT) questionnaire when using Qlosi™ at week 4 compared to baseline.",[29,168,82],"Glasses","2025-08-07",{"date":171,"type":37},"2025-08-12",{"date":173,"type":37},"2025-07-18",{"date":175,"type":22},"2025-11-15",{"name":43,"class":44},2,""]